SCHEMBL10883109

SCHEMBL10883109

O=C1CN(C(=O)c2ccccc2)CCN1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.57
POLB P06746 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
KMT2A Q03164 3/20 0.54
MEN1 O00255 1/20 0.54
RAB9A P51151 1/20 0.54
HRH3 Q9Y5N1 1/20 0.53
HPGD P15428 1/20 0.51
HSP90AA1 P07900 1/20 0.50
PARP1 P09874 2/20 0.47
DDB1 Q16531 1/20 0.47
CRBN Q96SW2 1/20 0.47
ACHE P22303 1/20 0.46
USP2 O75604 1/20 0.46
ALDH1A1 P00352 1/20 0.46
TACR3 P29371 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21170645 0.84 HRH3 (0.54) L3MBTL1POLBTDP1KMT2AMEN1
SCHEMBL14117676 0.84 HRH3 (0.54) SIGMAR1L3MBTL1POLBTDP1KMT2A
SCHEMBL12093445 0.84 PKM (0.67) POLBTDP1KMT2AMEN1RAB9A
SCHEMBL4751256 0.84 HSP90AA1 (0.55) POLBTDP1KMT2ARAB9AHRH3
SCHEMBL29908037 0.83 HPGD (0.59) L3MBTL1POLBTDP1KMT2AMEN1
SCHEMBL28837075 0.83 HPGD (0.59) L3MBTL1POLBTDP1KMT2AMEN1
SCHEMBL17925958 0.83 SIGMAR1 (0.51) SIGMAR1L3MBTL1HPGDDDB1CRBN
SCHEMBL16026473 0.83 HSP90AA1 (0.53) L3MBTL1POLBTDP1KMT2AMEN1
SCHEMBL17533885 0.82 TSHR (0.56) L3MBTL1POLBTDP1KMT2AMEN1
SCHEMBL17850234 0.82 POLB (0.59) L3MBTL1POLBTDP1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110396067-B 1, 4-disubstituted-2-piperazinone compound and pharmaceutical application thereof 复旦大学 2022-07-08 CN disclosed
CN-104046246-B The chemical-mechanical planarization of tungsten-containing substrate 气体产品与化学公司 2016-06-15 CN disclosed
US-7566717-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2009-07-28 US disclosed
US-20080275238-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS PALLE VENKATA 2008-11-06 US disclosed
EP-0107423-B1 NOVEL CHROMANS AND CHROMENES BEECHAM GROUP PLC (GB) 1986-07-23 EP disclosed
US-4496565-A HYPOTENSIVE AGENTS BEECHAM GROUP P.L.C. (GB) 1985-01-29 US disclosed
EP-0107423-A1 Novel chromans and chromenes BEECHAM GROUP PLC (GB) 1984-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275238-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS KCNH1, SDHA, COQ8A SIGMAR1 4373/4885L3MBTL1 1085/4885POLB 2485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.